SBIR TOPIC 252 -COMMERCIALLY VIABLE SYNTHESIS OF MULTIFUNCTIONAL CANCER RECEPTOR

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO0800057
Agency Tracking Number: N43CO0800057
Amount: $135,973.00
Phase: Phase I
Program: SBIR
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
NANOPARTICLE BIOCHEM, INC.
2814 WILD PLUM CT., COLUMBIA, MO, 65201
DUNS: 787875579
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Anandhi Upendran
 () -
Business Contact
Phone: (573) 639-2615
Research Institution
N/A
Abstract
In this Phase I SBIR contract, Nanoparticle Biochem Inc (NBI) proposes to develop commercially viable synthetic methodology for the production of multifunctional gold Nanoparticle-bombesin conjugate. Gold Nanoparticle-bombesin (AuNP-BBN) conjugate is a potential clinical imaging and therapeutic agent for the detection and treatment of GRP receptors over-expressing prostate and breast cancers. Average size of AuNP-BBN nanoconjugates are 14 nm. AuNP-BBN conjugate was developed by the funds from NCI's cancer nanoscience and nanotechnology platform grant and it is licensed to Nanoparticle Biochem Inc. Currently available methodology can yield only 10 mg quantities of AuNP-BBN. Developing a commercially-viable strategy for synthesizing AuNP-BBN nanoconjugate would significantly help in performing preclinical cancer imaging efficacy studies in larger animal models and preclinical toxicity studies.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government